myelodysplastic syndromes
Recently Published Documents


TOTAL DOCUMENTS

6153
(FIVE YEARS 910)

H-INDEX

121
(FIVE YEARS 12)

2022 ◽  
Vol 42 (3) ◽  
pp. 299-305
Author(s):  
Akriti G. Jain ◽  
Ling Zhang ◽  
John M. Bennett ◽  
Rami Komrokji

2022 ◽  
Vol 76 ◽  
pp. 102090
Author(s):  
Amy M. Linabery ◽  
Michelle A. Roesler ◽  
Michaela Richardson ◽  
Erica D. Warlick ◽  
Phuong L. Nguyen ◽  
...  

2022 ◽  
pp. 391-411
Author(s):  
Inga Hofmann ◽  
Nobuko Hijiya ◽  
Mohamed Tarek Elghetany

2022 ◽  
pp. 106789
Author(s):  
Stefan G.C. Mestrum ◽  
Eline M.P. Cremers ◽  
Norbert C.J. de Wit ◽  
Roosmarie J.M. Drent ◽  
Frans C.S. Ramaekers ◽  
...  

2021 ◽  
pp. 1-9
Author(s):  
Sílvia Saumell ◽  
Miranda Fernández-Serrano ◽  
Alba Mesa ◽  
Félix López-Cadenas ◽  
Leonor Arenillas ◽  
...  

Author(s):  
Amer M. Zeidan ◽  
Isaac Wayne Boss ◽  
CL Beach ◽  
Wilbert B. Copeland ◽  
Ethan Greene Thompson ◽  
...  

Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase inhibitory immune checkpoint (ICP) molecule expression. We conducted the first randomized phase 2 study of azacitidine plus the ICP inhibitor durvalumab versus azacitidine monotherapy as first-line treatment of higher-risk myelodysplastic syndromes (HR-MDS). Patients (N=84) received azacitidine 75 mg/m2 subcutaneously (days 1-7) with (Arm A) or without (Arm B) durvalumab 1500 mg intravenously on day 1 every 4 weeks. After a median follow-up of 15.25 months, 8 patients in Arm A and 6 in Arm B remained on treatment. Patients in Arms A and B received a median of 7.9 and 7.0 treatment cycles, respectively, with 73.7% and 65.9% completing ≥4 cycles. The overall response rate (primary endpoint) was 61.9% in Arm A (26/42) and 47.6% in Arm B (20/42; P=0.18), and median overall survival was 11.6 months (95% CI: 9.5, nonevaluable) versus 16.7 months (95% CI: 9.8, 23.5) (P=0.74). Durvalumab-related adverse events (AEs) were reported by 71.1% of patients; azacitidine-related AEs were reported by 82% (A) and 81% (B). Grade 3 or 4 hematologic AEs were reported in (Arm A vs B) 89.5% vs 68.3% of patients. Patients with TP53 mutations tended to have a worse response than patients without these mutations. Azacitidine increased PD-L1 (CD274) surface expression on bone marrow granulocytes and monocytes, but not blasts, in both arms. In summary, combining durvalumab and azacitidine in patients with HR-MDS was feasible, but with more toxicities and without significant improvement in clinical outcomes over azacitidine alone. ClinicalTrials.gov: NCT02775903


Sign in / Sign up

Export Citation Format

Share Document